Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Raised by TCW Group Inc.

TCW Group Inc. lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 555,133 shares of the biopharmaceutical company’s stock after acquiring an additional 2,852 shares during the quarter. TCW Group Inc.’s holdings in Gilead Sciences were worth $44,974,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in GILD. Norges Bank purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $1,301,624,000. Clearbridge Investments LLC lifted its position in shares of Gilead Sciences by 179.0% in the 3rd quarter. Clearbridge Investments LLC now owns 4,543,985 shares of the biopharmaceutical company’s stock valued at $340,526,000 after acquiring an additional 2,915,141 shares in the last quarter. abrdn plc lifted its position in shares of Gilead Sciences by 89.0% in the 4th quarter. abrdn plc now owns 3,764,107 shares of the biopharmaceutical company’s stock valued at $304,930,000 after acquiring an additional 1,772,887 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in Gilead Sciences in the 4th quarter worth approximately $133,584,000. Finally, AEGON ASSET MANAGEMENT UK Plc purchased a new stake in Gilead Sciences in the 4th quarter worth approximately $63,971,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD traded down $1.63 during midday trading on Thursday, reaching $66.17. 5,596,381 shares of the company’s stock were exchanged, compared to its average volume of 7,252,457. The company’s 50 day simple moving average is $68.77 and its two-hundred day simple moving average is $74.70. The firm has a market capitalization of $82.44 billion, a PE ratio of 183.78, a price-to-earnings-growth ratio of 1.35 and a beta of 0.22. Gilead Sciences, Inc. has a 12 month low of $64.33 and a 12 month high of $87.86. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. During the same period last year, the firm posted $1.37 EPS. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. Equities research analysts expect that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.65%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Analyst Ratings Changes

GILD has been the subject of a number of research analyst reports. UBS Group cut their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 27th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Friday, April 26th. Wells Fargo & Company cut their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a report on Monday, March 4th. Finally, Royal Bank of Canada lowered their target price on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating on the stock in a research note on Friday, April 26th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Hold” and an average target price of $83.69.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.